VEGZELMA Drug Profile
Summary for Tradename: VEGZELMA
| High Confidence Patents: | 0 |
| Applicants: | 1 |
| BLAs: | 1 |
| Recent Clinical Trials: | See clinical trials for VEGZELMA |
Recent Clinical Trials for VEGZELMA
Identify potential brand extensions & biosimilar entrants
| Sponsor | Phase |
|---|---|
| Neonc Technologies, Inc. | Phase 1/Phase 2 |
| Roswell Park Cancer Institute | Phase 2 |
| National Cancer Institute (NCI) | Phase 2 |
Pharmacology for VEGZELMA
| Mechanism of Action | Vascular Endothelial Growth Factor Inhibitors Vascular Endothelial Growth Factor-directed Antibody Interactions |
| Established Pharmacologic Class | Vascular Endothelial Growth Factor Inhibitor |
Note on Biologic Patents
Matching patents to biologic drugs is far more complicated than for small-molecule drugs.
DrugPatentWatch employs three methods to identify biologic patents:
- Brand-side disclosures in response to biosimilar applications
- DrugPatentWatch analysis and company disclosures
- Patents from broad patent text search
These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.
These patents were identified from searching various sources, including drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.
For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.
1) High Certainty: US Patents for VEGZELMA Derived from Brand-Side Litigation
No patents found based on brand-side litigation
2) High Certainty: US Patents for VEGZELMA Derived from DrugPatentWatch Analysis and Company Disclosures
No patents found based on company disclosures
3) Low Certainty: US Patents for VEGZELMA Derived from Patent Text Search
No patents found based on company disclosures
VEGZELMA Market Dynamics and Financial Trajectory
VEGZELMA, Celltrion’s bevacizumab biosimilar, competes in a mature U.S. market with multiple approved products, declining originator sales, and increasing payer pressure. The product was FDA-approved in September 2022 as bevacizumab-adcd for the same oncology indications as Avastin, including colorectal, lung, brain, ovarian, cervical, and renal cancers. Celltrion does not report VEGZELMA revenue as a separate line item, so product-specific sales, margin, and profitability cannot be verified from public financial statements. The commercial outlook depends on formulary access, hospital contracting, oncology-provider adoption, and price competition with Mvasi, Zirabev, Alymsys, and Avzivi.
What is VEGZELMA and who markets it?
VEGZELMA is the U.S. brand name for bevacizumab-adcd, a monoclonal antibody biosimilar to Genentech/Roche’s Avastin, or bevacizumab. Celltrion developed the product as CT-P16 and markets it through Celltrion USA and regional commercial partners.
| Attribute | VEGZELMA |
|---|---|
| Active ingredient | Bevacizumab-adcd |
| Reference product | Avastin, bevacizumab |
| Developer | Celltrion |
| U.S. application | Biologics License Application under the 351(k) biosimilar pathway |
| FDA approval | September 27, 2022 |
| Interchangeability | Not FDA-designated interchangeable |
| Primary market | Oncology infusion and hospital channels |
| Dosage form | Intravenous infusion |
| Product type | Biosimilar monoclonal antibody |
| Main competitors | Mvasi, Zirabev, Alymsys, Avzivi |
| U.S. Orange Book listing | No. Biologics are tracked primarily through the Purple Book |
The FDA found VEGZELMA highly similar to Avastin, with no clinically meaningful differences in safety, purity, or potency. The approval covers the indications for which Avastin was licensed, subject to the scope of the FDA label and applicable patent or regulatory restrictions.[1]
What is the FDA and regulatory status of VEGZELMA?
VEGZELMA is FDA-approved but is not designated interchangeable with Avastin. That distinction affects substitution. A non-interchangeable biosimilar can be prescribed by a physician, but a pharmacist generally cannot substitute it automatically under state pharmacy law without prescriber authorization.
The product is also authorized in Europe under the name Vegzelma. The European Commission granted marketing authorization in 2022 after review by the European Medicines Agency. European uptake depends heavily on national tendering and hospital procurement rather than retail pharmacy substitution.[2]
U.S. regulatory milestones
| Date | Event |
|---|---|
| February 26, 2004 | Avastin first approved by FDA |
| February 2016 | Twelve-year U.S. reference-product exclusivity for Avastin ended |
| September 27, 2022 | FDA approved VEGZELMA |
| 2022 onward | U.S. commercial entry into the bevacizumab biosimilar market |
| 2023-2024 | Continued expansion of biosimilar competition and payer contracting |
VEGZELMA does not receive a separate period of reference-product exclusivity because it was approved under the abbreviated biosimilar pathway. Its commercial protection comes primarily from manufacturing know-how, supply reliability, contracting, regulatory compliance, and any applicable patent rights.
When does Avastin lose exclusivity, and what does that mean for VEGZELMA?
Avastin’s principal U.S. biologic exclusivity expired in February 2016, while key composition-of-matter patent protection also expired before VEGZELMA entered the market. The commercial barrier is therefore no longer reference-product exclusivity. The relevant competition is between multiple biosimilar manufacturers.
The FDA does not list biologics in the Orange Book in the same manner as small-molecule drugs. Avastin and its biosimilars are included in the Purple Book, which identifies licensed biological products and biosimilarity or interchangeability determinations.[3]
| Exclusivity or patent issue | Commercial effect on VEGZELMA |
|---|---|
| Avastin 12-year biologic exclusivity | Expired before VEGZELMA approval |
| Core Avastin patent estate | No longer a major barrier to U.S. entry |
| Orange Book listing | Not applicable to the biologic product in the traditional sense |
| Purple Book status | VEGZELMA listed as a biosimilar to Avastin |
| Interchangeability | No automatic substitution status |
| Product-specific patents | May cover manufacturing or formulation details, but do not recreate Avastin exclusivity |
How many biosimilars compete with VEGZELMA?
The U.S. bevacizumab market has become structurally competitive. VEGZELMA entered after Amgen’s Mvasi and Pfizer’s Zirabev had already established market access. Alymsys expanded the field, and Avzivi added another approved competitor.
| Product | Nonproprietary name | Sponsor | FDA status |
|---|---|---|---|
| Avastin | Bevacizumab | Genentech/Roche | Reference product |
| Mvasi | Bevacizumab-awwb | Amgen | Biosimilar |
| Zirabev | Bevacizumab-bvzr | Pfizer | Biosimilar |
| Alymsys | Bevacizumab-maly | Amneal/Mabxience | Biosimilar |
| VEGZELMA | Bevacizumab-adcd | Celltrion | Biosimilar |
| Avzivi | Bevacizumab-tnjn | Bio-Thera/partners | Biosimilar |
This market structure limits pricing power. Hospital systems and group purchasing organizations can use competing suppliers to negotiate discounts, secure dual sourcing, and reduce dependence on any single manufacturer.
How does VEGZELMA compare with Mvasi and Zirabev?
Mvasi and Zirabev entered earlier and have had more time to build contracts with oncology practices, hospitals, distributors, and integrated delivery networks. VEGZELMA’s commercial advantage is likely to depend on Celltrion’s ability to offer competitive pricing while maintaining supply consistency.
| Factor | VEGZELMA | Mvasi | Zirabev |
|---|---|---|---|
| U.S. market entry | Later entrant | Early entrant | Early entrant |
| Sponsor scale | Large global biosimilar specialist | Large biologics manufacturer | Large pharmaceutical company |
| Interchangeability | No | No | No |
| Main commercial lever | Price, supply, contracting | Installed account base and scale | Procurement reach and portfolio breadth |
| Primary risk | Late-entry share capture | Price erosion | Price erosion |
VEGZELMA is unlikely to win the market through clinical differentiation because biosimilars are expected to deliver comparable clinical outcomes. The principal competitive variables are net price, availability, contracting support, pharmacovigilance, and provider familiarity.
What is the financial trajectory of VEGZELMA?
Celltrion does not separately disclose VEGZELMA revenue in its public annual reports. Reported results combine multiple biosimilar and pharmaceutical products, which prevents a verified product-level revenue calculation.
The financial trajectory can therefore be assessed through market structure and parent-company disclosures rather than a standalone VEGZELMA income statement.
Revenue visibility
| Financial metric | Publicly available for VEGZELMA? | Interpretation |
|---|---|---|
| Annual product revenue | No separate disclosure identified | Cannot verify sales or growth |
| Gross margin | No | Depends on transfer pricing, manufacturing cost, and discounts |
| Net price | No public standardized figure | Contract prices vary by account |
| Market share | Limited public visibility | Claims data and procurement data are required |
| Celltrion segment revenue | Yes | Includes multiple products and cannot isolate VEGZELMA |
| R&D expense | Not allocated by product | Portfolio-level reporting |
| Product profitability | Not disclosed | Requires internal cost and contracting data |
Celltrion reported consolidated revenue of approximately KRW 2.18 trillion for 2023, reflecting its broader pharmaceutical and biosimilar portfolio rather than VEGZELMA alone.[4] The company’s biosimilar strategy has emphasized oncology and immunology products, with commercial scale distributed across Remsima, Herzuma, Truxima, and newer products. VEGZELMA contributes to that portfolio but is not individually material enough, or not reported in a manner, that permits a public revenue bridge.
Base-case financial outlook
The base case is moderate revenue growth followed by price compression:
- Initial sales increase as additional hospitals and oncology practices add VEGZELMA to formularies.
- Net pricing declines as four or more biosimilars compete for the same Avastin volume.
- Revenue growth becomes volume-led rather than price-led.
- Gross margin depends on manufacturing scale and the extent of discounts required to win tenders.
- Profitability improves only if Celltrion achieves sufficient production utilization and avoids excessive channel concessions.
A late entrant can still gain share in a biosimilar market, but the financial return is generally lower than for a first entrant because procurement customers already have approved alternatives.
What market dynamics affect VEGZELMA sales?
Hospital and oncology procurement
Bevacizumab is administered by intravenous infusion in hospitals, ambulatory infusion centers, and oncology clinics. Procurement decisions are usually made by health systems, pharmacy and therapeutics committees, oncology networks, and group purchasing organizations.
The product is not primarily driven by retail pharmacy advertising. Commercial success depends on:
- Contracted reimbursement and acquisition cost
- Reliable vial supply
- Waste reduction and vial-size economics
- Provider confidence in manufacturing consistency
- Electronic ordering and billing integration
- Payer policies for physician-administered drugs
- Availability of more than one approved supplier
Payer and reimbursement pressure
Biosimilar adoption is affected by reimbursement rules, including buy-and-bill economics under Medicare Part B and commercial payer policies. Providers may select a biosimilar when reimbursement preserves or improves the spread between acquisition cost and payer reimbursement.
The spread can narrow as payers and hospitals obtain larger discounts. This creates a tension for Celltrion: aggressive price reductions may accelerate volume but reduce revenue per vial and margin.
Indication mix
VEGZELMA competes across several oncology indications, but the volume mix is not uniform. High-volume uses include metastatic colorectal cancer, non-small-cell lung cancer, and ovarian cancer. Glioblastoma, cervical cancer, and renal cancer contribute additional demand but may have different treatment patterns and payer controls.
The product has no separate clinical differentiation by indication. Its share must be built across treatment protocols where Avastin and competing bevacizumab biosimilars are accepted.
What is the competitive risk from new bevacizumab biosimilars?
The principal risk is continued price erosion rather than clinical displacement. Every additional approved product increases leverage for purchasers and reduces the probability that one biosimilar can sustain a premium.
Avzivi and any future entrants can pressure VEGZELMA in three ways:
- Lowering contracted net prices
- Offering bundled discounts with other oncology products
- Providing secondary supply that reduces the value of Celltrion’s reliability advantage
Celltrion can offset some of this pressure through portfolio contracting. A supplier with several biosimilars may offer hospitals a broader oncology package, but this strategy can also reduce average net price across the portfolio.
What patents protect VEGZELMA and its manufacturing process?
VEGZELMA is not protected by the Avastin patent estate in the same way as the originator. The commercial patent analysis must distinguish between:
- Patents covering bevacizumab itself
- Patents covering VEGZELMA’s cell line, production process, purification, formulation, or analytical methods
- Patents covering specific methods of treating cancer
- Patents held by third parties that could create manufacturing or supply risk
Public regulatory approval does not establish freedom to operate in every jurisdiction. Biologic manufacturing patents can remain relevant even after originator composition patents expire. These rights may affect production sites, cell-culture systems, purification steps, or formulation technologies.
No major public U.S. Paragraph IV litigation campaign against VEGZELMA is associated with the product’s FDA approval. Paragraph IV litigation is primarily a Hatch-Waxman mechanism for small-molecule ANDAs. Biosimilar disputes are generally handled through the Biologics Price Competition and Innovation Act patent-exchange framework, often called the patent dance, and through conventional patent litigation.
What generic and biosimilar launch risks exist for VEGZELMA?
VEGZELMA faces biosimilar launch risk rather than conventional generic substitution risk.
| Risk | Potential effect |
|---|---|
| Additional bevacizumab biosimilars | Lower net price and slower share growth |
| No interchangeability designation | More prescriber and payer friction |
| Hospital incumbent relationships | Higher customer-acquisition cost |
| Supply disruption | Loss of formulary position |
| Low oncology margins | Reduced return on manufacturing investment |
| Patent or manufacturing disputes | Delayed expansion in selected markets |
| Tender concentration in Europe | Rapid volume gains but severe price erosion |
| Originator contracting response | Avastin may retain accounts through rebates or service |
What geographic markets are important for VEGZELMA?
The United States and Europe are the most important high-value markets, but their commercial mechanics differ.
The U.S. market rewards contracting, reimbursement execution, and account-level adoption. Europe relies more heavily on national reimbursement decisions, hospital tenders, and country-specific pricing controls. Emerging markets can provide volume, but pricing is typically lower and local registration, distribution, and manufacturing requirements can increase complexity.
Celltrion’s global biosimilar infrastructure gives VEGZELMA access to a broad commercial platform. The product’s financial value will depend on the balance between high-price U.S. sales and lower-price, tender-driven international volume.
What is the likely revenue exposure from Avastin erosion?
Roche reported Avastin sales of approximately CHF 3.0 billion in 2023, down from earlier periods as biosimilar competition expanded.[5] This decline creates a large addressable market, but the revenue is distributed among multiple biosimilars and is reduced by price erosion.
A simple market-sizing framework is:
| Variable | Impact on VEGZELMA |
|---|---|
| Avastin addressable sales | Sets the gross opportunity |
| Biosimilar penetration | Determines volume available to competitors |
| VEGZELMA share | Determines product volume |
| Net price after rebates | Determines revenue |
| Manufacturing cost | Determines gross margin |
| Account retention | Determines recurring revenue |
| International tender wins | Determines geographic scale |
The opportunity is therefore substantial at the category level but limited at the individual-product level. VEGZELMA’s commercial success does not require replacing Avastin entirely. It requires securing durable share against several biosimilar suppliers at an acceptable net price.
Key Takeaways
- VEGZELMA is Celltrion’s FDA-approved bevacizumab biosimilar, marketed as bevacizumab-adcd.
- FDA approval occurred on September 27, 2022.
- The product is not designated interchangeable with Avastin.
- Avastin’s principal exclusivity barriers expired before VEGZELMA entered the U.S. market.
- The U.S. market includes Mvasi, Zirabev, Alymsys, VEGZELMA, and Avzivi.
- Celltrion does not publicly disclose VEGZELMA-specific revenue, pricing, margin, or market share.
- The product’s financial trajectory is likely volume-driven, with ongoing net-price pressure.
- Hospital contracting, supply reliability, payer reimbursement, and oncology-network access are more important than clinical differentiation.
- No major public Paragraph IV litigation campaign is central to VEGZELMA’s U.S. launch.
- Manufacturing patents, process know-how, and geographic regulatory approvals remain relevant to long-term supply and market access.
FAQs
Is VEGZELMA interchangeable with Avastin?
No. FDA approved VEGZELMA as a biosimilar to Avastin but did not designate it interchangeable. Substitution rules depend on state law and payer or prescriber policy.
Does VEGZELMA have an Orange Book patent listing?
No conventional Orange Book listing applies. Biologic reference products and biosimilars are primarily tracked through the FDA Purple Book.
Who owns VEGZELMA?
Celltrion developed and markets VEGZELMA. Regional commercialization may involve local affiliates or distribution partners.
Is VEGZELMA cheaper than Avastin?
Biosimilars generally compete through lower net prices, but actual discounts vary by hospital, payer, distributor, and purchasing contract. A single public price does not represent the market-wide net price.
Can VEGZELMA replace Avastin in all approved cancer indications?
VEGZELMA’s FDA label covers the Avastin indications identified in its approval. Actual use depends on physician judgment, payer policy, treatment guidelines, and institutional formulary status.
References
- U.S. Food and Drug Administration. (2022, September 27). FDA approves biosimilar to Avastin. https://www.fda.gov
- European Medicines Agency. (2022). Vegzelma: EPAR. https://www.ema.europa.eu
- U.S. Food and Drug Administration. (2024). Purple Book: Database of licensed biological products. https://purplebooksearch.fda.gov
- Celltrion, Inc. (2024). Annual report 2023. https://www.celltrion.com
- Roche Holding AG. (2024). Annual report 2023. https://www.roche.com/annual-report
More… ↓
